Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from different endocrine glands (such as the pituitary, the parathyroid or the neuroendocrine adrenal glands), endocrine islets (within the thyroid or pancreas) as well as from endocrine cells dispersed be...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Grozinsky-Glasberg, S, Shimon, I, Korbonits, M, Grossman, AB
Natura:	Journal article
Lingua:	English
Pubblicazione:	2008

Documenti analoghi

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
di: Grozinsky-Glasberg, S, et al.
Pubblicazione: (2008)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
di: Kaltsas, G, et al.
Pubblicazione: (2005)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
di: King, C, et al.
Pubblicazione: (1993)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
di: Gupta, P, et al.
Pubblicazione: (2014)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
di: Ur, E, et al.
Pubblicazione: (1993)

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
di: Su-Chen Li, et al.
Pubblicazione: (2012-01-01)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
di: Baldelli Roberto, et al.
Pubblicazione: (2010-03-01)

Somatostatin analogues therapy in gastroenteropancreatic neuroendocrine tumours: current aspects and new perspectives
di: Roberto eBaldelli
Pubblicazione: (2014-02-01)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
di: Sen Gupta, P, et al.
Pubblicazione: (2014)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
di: Rihards Saksis, et al.
Pubblicazione: (2023-02-01)

Efficacy of somatostatine analogues in survival and quality of life of a frail patient with poorly differentiated biliary neuroendocrine tumour
di: Marco Alì, et al.
Pubblicazione: (2015-10-01)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
di: Hubina, E, et al.
Pubblicazione: (2006)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
di: Ralf S. Eschbach, et al.
Pubblicazione: (2023-01-01)

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
di: Chahal, H, et al.
Pubblicazione: (2011)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
di: Cakir, M, et al.
Pubblicazione: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
di: Cakir, M, et al.
Pubblicazione: (2010)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
di: Peter Wiesli, et al.
Pubblicazione: (2019-10-01)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
di: Den Gupta, P, et al.
Pubblicazione: (2011)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
di: Grozinsky-Glasberg, S, et al.
Pubblicazione: (2011)

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.
di: Chahal, H, et al.
Pubblicazione: (2010)

Update on neuroendocrine tumours
di: Grossman, AB
Pubblicazione: (2012)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
di: Sebastian Krug, et al.
Pubblicazione: (2019-01-01)

Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
di: Halfdan Sorbye, et al.
Pubblicazione: (2020-06-01)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
di: Inbal Uri, et al.
Pubblicazione: (2018-07-01)

Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms.
di: Kaltsas, G, et al.
Pubblicazione: (2014)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
di: Kaltsas, G, et al.
Pubblicazione: (2001)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
di: Fernando Sebastian-Valles, et al.
Pubblicazione: (2023-03-01)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
di: Sheila D. Rustgi, et al.
Pubblicazione: (2021-05-01)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
di: Joana Lima Ferreira, et al.
Pubblicazione: (2021-05-01)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
di: Ström T, et al.
Pubblicazione: (2019-10-01)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
di: Wenjuan Liu, et al.
Pubblicazione: (2017-01-01)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
di: Ur, E, et al.
Pubblicazione: (1992)

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487
di: Carroll, P, et al.
Pubblicazione: (2003)

Growth hormone-releasing peptides (GHRP) and their analogues
di: Korbonits, M, et al.
Pubblicazione: (1996)

[Growth hormone-releasing peptides (GHRP) and their analogues]
di: Korbonits, M, et al.
Pubblicazione: (1996)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
di: Grozinsky-Glasberg, S, et al.
Pubblicazione: (2008)

Paraneoplastic syndromes secondary to neuroendocrine tumours.
di: Kaltsas, G, et al.
Pubblicazione: (2010)

Antiangiogenic effects of somatostatin analogues.
di: García de la Torre, N, et al.
Pubblicazione: (2002)

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
di: Pedro Marques, et al.
Pubblicazione: (2019-11-01)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
di: Jenkins, P, et al.
Pubblicazione: (2000)